Aug 24 (Reuters) - Biogen Inc :Imraldi(®), Biogen's Adalimumab Biosimilar referencing Humira(®), is approved in European Union.European commission granted a marketing authorization for Imraldi, an Adalimumab Biosimilar …
Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $336.56 to a high of $344.87. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of $339.94 on volume of 445,000 …
Nov 2 (Reuters) - Biogen Inc ::Biogen presents new data from long-term extension of phase 1b study of investigational alzheimer’s disease treatment aducanumab.Biogen Inc - ‍as of October 2017, Biogen and Eisai entered into a global …
Dec 22 (Reuters) - Biogen Inc ::BIOGEN RESPONDS TO COVERAGE RECOMMENDATION BY THE CANADIAN DRUG EXPERT COMMITTEE (CDEC) FOR SPINRAZA, THE ONLY TREATMENT APPROVED FOR TREATMENT OF 5Q …